Form 4 for GYRE GYRE THERAPEUTICS, INC.
Accepted 2026-05-22 18:19:30 ET · period of report 2026-05-20 · accession 0001140361-26-022642 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-05-22 18:19 | 2026-05-20+ | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +22.2K | 712.8K | +3% | +$16.7K |
| DM | 2026-05-22 18:19 | 2026-05-20+ | GYRE | Ye Weiguo | COO | S - Sale+OE | $6.15 | -22.2K | 700.0K | -3% | -$136.7K |
| DM | 2026-05-22 18:19 | 2026-05-20+ | GYRE | Ye Weiguo | COO | M - OptEx | $0.00 | -22.2K | 904.9K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-20 | M | A | 9,400 | $0.75 | 709,400 | D | — | — | |
| 2 | Common | Common Stock | 2026-05-20 | S | D | 9,400 | $6.15 | 700,000 | D | — | — | (F1) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0908 to $6.2935. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2026-05-21 | M | A | 12,820 | $0.75 | 712,820 | D | — | — | |
| 4 | Common | Common Stock | 2026-05-21 | S | D | 12,820 | $6.15 | 700,000 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.22. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-05-20 | M | D | 9,400 | $0.00 | 917,715 | D | $0.75 · — to 2030-10-31 | 9,400 Common Stock | (F3) These options are vested in full. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-05-21 | M | D | 12,820 | $0.00 | 904,895 | D | $0.75 · — to 2030-10-31 | 12,820 Common Stock | (F3) These options are vested in full. |